Published in
Taylor and Francis Group, Journal of Medical Economics (JME), 1(26), p. 283-292, 2023
DOI: 10.1080/13696998.2023.2174748
Links
Tools
Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland
Journal article published in 2023 by
Andrea Favre-Bulle 
,
Goran Bencina ,
Shujing Zhang ,
Ruixuan Jiang ,
Daniel Andritschke ,
Arjun Bhadhuri
,
Goran Bencina ,
Shujing Zhang ,
Ruixuan Jiang ,
Daniel Andritschke ,
Arjun Bhadhuri
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 